These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

856 related items for PubMed ID: 17574038

  • 1. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD.
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [Abstract] [Full Text] [Related]

  • 2. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
    Chu QD, Panu L, Holm NT, Li BD, Johnson LW, Zhang S.
    J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
    Mizell J, Smith M, Li BD, Ampil F, Chu QD.
    Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
    [Abstract] [Full Text] [Related]

  • 4. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT, Abreo F, Johnson LW, Li BD, Chu QD.
    Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
    [Abstract] [Full Text] [Related]

  • 5. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
    Wolfort R, de Benedetti A, Nuthalapaty S, Yu H, Chu QD, Li BD.
    Surgery; 2006 Aug; 140(2):161-9. PubMed ID: 16904965
    [Abstract] [Full Text] [Related]

  • 6. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD.
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M.
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [Abstract] [Full Text] [Related]

  • 13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 Jun; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 14. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.
    J Clin Oncol; 2007 Oct 01; 25(28):4423-30. PubMed ID: 17906205
    [Abstract] [Full Text] [Related]

  • 15. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
    Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, Md QC, Li BD.
    Ann Surg Oncol; 2008 Nov 01; 15(11):3207-15. PubMed ID: 18719964
    [Abstract] [Full Text] [Related]

  • 16. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y, Booser DJ, Sneige N.
    Cancer; 2005 May 01; 103(9):1763-9. PubMed ID: 15786420
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients.
    Parker CC, Kim RH, Li BD, Chu QD.
    J Surg Oncol; 2012 Sep 15; 106(4):393-8. PubMed ID: 22473623
    [Abstract] [Full Text] [Related]

  • 19. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R.
    Cancer Res; 1993 Oct 15; 53(20):4960-70. PubMed ID: 8104689
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.